mirage

Nasal delivery of recombinant human growth hormone with pheroid technology / Dewald Steyn

Boloka/Manakin Repository

Show simple item record

dc.contributor.author Steyn, Johan Dewald
dc.date.accessioned 2009-03-02T15:26:08Z
dc.date.available 2009-03-02T15:26:08Z
dc.date.issued 2006
dc.identifier.uri http://hdl.handle.net/10394/1276
dc.description Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2007.
dc.description.abstract Over the past couple of years there has been rapid progress in the development and design of safe and effective delivery systems for the administration of protein and peptide drugs. The effective delivery of these type of drugs are not always as simple as one may think, due to various inherent characteristics of these compounds. Due to the hydrophilic nature and molecular size of peptide and protein drugs, such as recombinant human growth hormone, they are poorly absorbed across mucosal epithelia, both transcellularly and paracellularly. This problem can be overcome by the inclusion of absorption enhancers in peptide and protein drug formulations but this is not necessarily the best method to follow. This investigation focussed specifically on the evaluation of the ability of the PheroidTM carrier system to transport recombinant human growth hormone across mucosal epithelia especially when administered via the nasal cavity. The PheroidTM delivery system is a patented system consisting of a unique submicron emulsion type formulation. The PheroidTM delivery system, based on PheroidTM technology, will for ease of reading be called Pheroid(s) only throughout the rest of this dissertation. The Pheroid carrier system is a unique microcolloidal drug delivery system. A Pheroid is a stable structure within a novel therapeutic system which can be manipulated in terms of morphology, structure, size and function. Pheroids consist mainly of plant and essential fatty acids and can entrap, transport and deliver pharmacologically active compounds and other useful substances to the desired site of action. The specific objectives of this study can be summarised as follows: a literature study on Pheroid technology; a literature study on chitosan and N-trimethyl chitosan chloride; a literature study on recombinant human growth hormone (somatropin); a literature study on nasal drug administration; formulation of a suitable Pheroid carrier; entrapment of somatropin in the Pheroid carrier, and in vivo evaluation of nasal absorption of somatropin in Sprague-Dawley rats.
dc.publisher North-West University
dc.subject Recombinant human growth hormone (rhGH) en
dc.subject Pheroid vesicles en
dc.subject Pheroid microsponges en
dc.subject N-trimethyl chitosan chloride (TMC) en
dc.subject Nasal administration en
dc.title Nasal delivery of recombinant human growth hormone with pheroid technology / Dewald Steyn en
dc.type Thesis en
dc.description.thesistype Masters


Files in this item

This item appears in the following Collection(s)

  • ETD@PUK [5159]
    This collection contains the original digitized versions of research conducted at the North-West University (Potchefstroom Campus)

Show simple item record

Search the NWU Repository


Advanced Search

Browse

My Account

Statistics